2018

Current Medical and Surgical Management of Esophageal Diseases

www.bcm.edu/surgical-conference

Scientific Program

February 23-24
Four Seasons Hotel Houston
In its inaugural year, the course is designed for the wide spectrum of generalists and specialists who diagnose and manage esophageal related diseases. Didactic talks, panel discussions and Q&A sessions will delve into diagnostic and interventional strategies for gastroesophageal reflux disease, achalasia, Barrett’s esophagus and esophageal cancer. Featuring a world-renowned international faculty, the Current Medical and Surgical Management of Esophageal Diseases Conference offers the opportunity to review state-of-the-art concepts and techniques.

**PROGRAM OVERVIEW**

**PLANNING COMMITTEE**

Elaine Allbritton
Jared Cordon
Ronnetta Eaton
Scott Holmes

Stephanie Jackson
Rizwan Moton
Amy Silva

**SPONSORED BY**

Baylor College of Medicine
Baylor St. Luke's Medical Center
LEARNING OBJECTIVES

1. Identify updated information to provide patient care in surgical areas including esophageal cancer, Barrett’s esophagus, and GERD.

2. Explain new techniques in collaborating and communicating when working with teams to ensure best practices in patient care, education, and research in the field of general thoracic and esophageal surgery.

3. Apply quality improvement in the areas of general thoracic and esophageal surgery.

4. Utilize updated information, as outlined in the program, related to surgical diagnosis and diseases.

5. Outline new techniques and studies along with innovative approaches related to patient care, medical knowledge, practice-based learning and improvement, and system based practices.

TARGET AUDIENCE
Our target audience includes: general and thoracic surgeons, gastroenterologists, critical care specialists, primary care physicians, nurses, residents, fellows, physician assistants and nurse practitioners.

EDUCATIONAL METHODS
Lectures
Panel Discussions
Question and Answer Sessions
Audio-Visual Presentations

ACCREDITATION
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Texas Heart Institute and Baylor College of Medicine. Texas Heart Institute is accredited by the ACCME to provide continuing medical education for physicians.

CME CREDIT INFORMATION
Texas Heart Institute designates this live activity for a maximum of 14 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
# PROGRAM

**Friday, February 23, 2018**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Activity</th>
<th>Speaker/Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 – 8:00 am</td>
<td>Registration and Breakfast</td>
<td></td>
</tr>
<tr>
<td>8:00 – 8:15 am</td>
<td>Welcome: Dr. Shawn Groth and Dr. David Sugarbaker</td>
<td></td>
</tr>
</tbody>
</table>

**Day 1: Benign Esophagus**

**Session I**

Moderator: Dr. David Sugarbaker

<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Activity</th>
<th>Speaker/Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:15 – 8:45 am</td>
<td>Personalized GERD Management</td>
<td>Dr. Stuart Spechler</td>
</tr>
<tr>
<td>8:46 – 9:01 am</td>
<td>Esophageal Testing: Indications and Implications for Medical and Surgical Management of Patients with GERD</td>
<td>Dr. Lubin Arevalo</td>
</tr>
<tr>
<td>9:02 – 9:17 am</td>
<td>Current Status of Endoluminal Therapies for Reflux (Esophyx/Tif, Muse, Arms, Stretta, etc.)</td>
<td>Dr. Wais F. Abidi</td>
</tr>
<tr>
<td>9:18 – 9:33 am</td>
<td>Anti-Reflux Surgery for Patients with End-Stage Lung Disease Pre and Post Transplant</td>
<td>Dr. Matthew Hartwig</td>
</tr>
<tr>
<td>9:34 – 9:49 am</td>
<td>Indications for Esophagectomy in Patients with GERD</td>
<td>Dr. Steve DeMeester</td>
</tr>
<tr>
<td>9:50 – 10:05 am</td>
<td>Linx for GPEH</td>
<td>Dr. Francis (Tripp) Buckley</td>
</tr>
<tr>
<td>10:05 – 10:25 am</td>
<td>Panel Discussion</td>
<td></td>
</tr>
<tr>
<td>10:26 – 10:40 am</td>
<td>Exhibit Hall Break</td>
<td></td>
</tr>
</tbody>
</table>

**Session II – Achalasia**

Moderator: Dr. Shawn Groth

<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Activity</th>
<th>Speaker/Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:45 – 11:00 am</td>
<td>Achalasia Overview: Update on Chicago Classification and the Therapeutic Implications</td>
<td>Dr. Lubin Arevalo</td>
</tr>
<tr>
<td>11:01 – 11:16 am</td>
<td>Current Status of Non-Myotomy Therapies for Achalasia (Medications, Botox, and Balloon Dilation)</td>
<td>Dr. Nisreen Husain</td>
</tr>
<tr>
<td>11:17 – 11:32 am</td>
<td>Debate: Heller vs. POEM</td>
<td>Dr. Matthew Hartwig and Dr. Jon Wee</td>
</tr>
<tr>
<td>11:33 – 11:53 am</td>
<td>Panel Discussion</td>
<td></td>
</tr>
<tr>
<td>11:55 am – 12:00 pm</td>
<td>Morning Wrap-up</td>
<td></td>
</tr>
</tbody>
</table>

**Session III – Barrett’s**

Moderator: Dr. Antoon (Toni) Lerut

<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Activity</th>
<th>Speaker/Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:45 – 2:00 pm</td>
<td>Overview, Epidemiology/Risk of Cancer, Indications for and Methods of Screening (Scope, Endosponge)</td>
<td>Dr. Hashem El-Serag</td>
</tr>
</tbody>
</table>

**About the Keynote Speaker**

Stuart Jon Spechler, MD is Chief of the Division of Gastroenterology and Co-Director of the Center for Esophageal Diseases at Baylor University Medical Center at Dallas, Co-Director of the Center for Esophageal Research at the Baylor Scott & White Research Institute, and Adjunct Professor of Medicine at Texas A&M Health Science Center College of Medicine and at Sun Yat-Sen University in Guangzhou, China. Prior to joining Baylor University Medical Center in January 2017, Dr. Spechler was the Chief of the Division of Gastroenterology for the VA North Texas Healthcare System, Professor of Medicine, and holder of the Berta M. and Cecil O. Patterson Chair in Gastroenterology at the University of Texas Southwestern Medical Center, and he had been the Director of the Center for Swallowing Disorders at the Beth Israel Deaconess Medical Center and Harvard Medical School in Boston, Massachusetts.
2:01 – 2:16 pm  PPIs VS. Anti-Reflux Surgery for Barrett’s
Dr. Steve DeMeester

2:17 – 2:37 pm  Endoluminal Therapy for Barrett’s (RFA, Cryo, PDT, etc.) and Strategies and Imaging Modalities for Post-Treatment Surveillance of Barrett’s
Dr. Sharmila Anandasabapathy

2:38 – 2:53 pm  In 2018, Is Esophagectomy Ever Indicated for Barrett’s Esophagus?
Dr. Antoon (Toni) Lerut

2:53 – 3:08 pm  Panel Discussion

3:10 – 3:25 pm  Exhibit Hall Break

Session IV – Complications
Moderator: Dr. Shawn Groth

3:30 – 3:45 pm  Endoluminal Therapies for Esophageal Leaks and Perforations (Stents, Clips, Suture)
Dr. Kalpesh Patel

3:46 – 4:01 pm  Endo-Vac for Management of Leaks and Perforations
Dr. Steve Leeds

4:02 – 4:17 pm  Esophageal Perforations: Is There Still a Role for Thoracotomy and Primary Repair?
Dr. Shawn Groth

4:18 – 4:33 pm  Management of Perforated Esophageal Cancer
Dr. Bryan Burt

4:34 pm – 4:54 pm  Panel Discussion

4:55 pm – 5:00 pm  Wrap-up and Adjourn

5:01 pm – 6:30 pm  Reception

Saturday, February 24, 2018

7:00 – 7:45 am  Breakfast

7:45 – 8:00 am  Welcome: Dr. Shawn Groth and Dr. David Sugarbaker

Day 2 – Esophageal Cancer

Session I – Malignant Disorders
Moderator: Dr. Bryan Burt

8:00 – 8:30 am  Keynote Opening: Historical Perspective on Esophagectomy
Dr. Antoon (Toni) Lerut

About the Keynote Speaker

Prof. Dr. Toni Lerut obtained his MD degree and his training in General Surgery at the Catholic University in Leuven Belgium after which he trained as a registrar in Thoracic Surgery to Mr. Ronald Belsey in Bristol, UK. In 1982 he obtained a guest scholarship in the Department of Surgery, University of Chicago (Prof. Dr.D. Skinner). These contacts furthered his interest in thoracic and esophageal surgery and thoracic oncology.

In 1994 Prof. Dr. Lerut was appointed as the Chairman of a newly established Department of General Thoracic Surgery, today considered as a leading centre in Thoracic and Esophageal surgery and Lung Transplantation attracting over time numerous international fellows.

Prof Lerut authored or co-authored over 350 articles in international peer reviewed journals, over 90 book chapters, and numerous editorials and reviews. He has been awarded honorary fellowships of several prestigious organisations e.g. American Association of Thoracic Surgery, American Surgical Association, The European Society of Thoracic Surgeons, , the Royal College of Surgeons in Ireland and Royal College of Surgeons of England. He has been a visiting Professor lecturing at numerous academic institutes.

Prof.Dr. Lerut has been President of the two major European Thoracic and Cardiothoracic societies i.e. The European Association for Cardio-Thoracic Surgery and The European Society of Thoracic Surgeons as well as the President of the International Society of Diseases of the Esophagus and the European Surgical Association. He is currently the Chairman of the UEMS Section of Thoracic Surgery.

8:31 – 8:46 am  Pre and Post-Treatment of EUS: Indications, Results, and Limitations
Dr. Kalpesh Patel

8:47 – 9:02 am  Neoadjuvant Chemotherapy Alone Versus Neoadjuvant Chemoradiation Therapy for Locally Advanced Esophageal Cancer
Dr. Brandon Smaglo
9:03 – 9:18 am  Management of Patients with Pet CR after Neoadjuvant Chemorads for Esophageal Cancer  
Dr. Stephen Swisher

9:19 – 9:34 am  Who Benefits from Adjuvant Therapy Following Neoadjuvant Chemoradiation Therapy and Esophagectomy with Negative Margins  
Dr. Brandon Smaglo

9:35 – 9:50 am  EMR and ESD for Early Stage Esophageal Cancer  
Dr. Mohammed Othman

9:51 – 10:11 am  Panel Discussion
10:12 – 10:37 am  Exhibit Hall Break

**Session II – Surgery for Locally Advanced Disease**  
Moderator: Dr. James Luketich

10:40 – 10:55 am  Principles of Surgery (Operative Approaches, Value of Lymphadenectomy)  
Dr. Antoon (Toni) Lerut

10:56 – 11:09 am  Brigham 3 Hole  
Dr. David Sugarbaker

11:10 – 11:25 am  Standard Laparoscopic/Thoracoscopic MIE  
Dr. Jon Wee

11:26 – 11:41 am  Robotic MIE - Dr. Abbas Abbas

11:42 – 11:57 am  Management of Complications after Esophagectomy  
Dr. Shawn Groth

11:58 am – 12:08 pm  Panel Discussion
12:09 – 12:14 pm  Morning Wrap-Up

**12:15 – 1:30 pm Lunch and Keynote Address**  
How to Optimize Outcomes from Minimally Invasive Esophagectomy  
Dr. James Luketich

**About the Keynote Speaker**

Dr. James D. Luketich is the Henry T. Bahnson Professor of Cardiothoracic Surgery, Chairman, Department of Cardiothoracic Surgery, Chief, Division of Thoracic and Foregut Surgery, Director, Thoracic Surgical Oncology, Director, UPMC Esophageal and Lung Surgery Institute, and Director, Mark Ravitch/Leon C. Hirsch Center for Minimally Invasive Surgery. He received his undergraduate degree from Old Dominion University, his Master’s degree in Biochemistry from Vanderbilt University, and his MD degree from the Medical College of Pennsylvania. He completed fellowships in thoracic and cardiothoracic surgery at the Cleveland Clinic, New York Hospital-Cornell University Medical Center, and Memorial Sloan-Kettering Cancer Center.

Dr. Luketich has established himself as a pioneer of a number of minimally invasive procedures, most notably minimally invasive esophagectomy. He has authored more than 500 papers and book chapters related to esophageal and lung disorders. He is Deputy Editor of Annals of Thoracic Surgery, and he is on the editorial board of Annals of Surgery. Dr. Luketich is also a Councilor of the American Association of Thoracic Surgery.

His current interests are focused on esophageal and lung cancer and management of gastroesophageal reflux disease, giant paraesophageal hernias, and other disorders of the esophagus.

**Session III – Controversies**  
Moderator: Dr. Stuart Spechler

1:35 – 1:50 pm  Botox vs. Gastric Emptying Procedure during Esophagectomy  
Dr. Abbas Abbas

1:51 – 2:06 pm  Conduit Revision after Esophagectomy  
Dr. James Luketich

2:07 – 2:19 pm  Salvage Esophagectomy  
Dr. Stephen Swisher

2:20 – 2:35 pm  5 Principles to Improve your Esophageal Surgery Outcomes  
Dr. David Sugarbaker

2:36 – 2:56 pm  Panel Discussion
2:57 – 3:10 pm  Wrap up and Adjourn
# Faculty

<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbas Abbas, MD</td>
<td>Steven Leeds, MD</td>
</tr>
<tr>
<td>Temple University</td>
<td>Baylor Scott &amp; White</td>
</tr>
<tr>
<td>Philadelphia, Pennsylvania</td>
<td>Houston, Texas</td>
</tr>
<tr>
<td>Wasif Abidi, MD, PhD</td>
<td>Antoon (Toni) Lerut, MD, PhD</td>
</tr>
<tr>
<td>Baylor College of Medicine</td>
<td>University Hospitals Leuven</td>
</tr>
<tr>
<td>Houston, Texas</td>
<td>Leuven, Belgium</td>
</tr>
<tr>
<td>Sharmila Anandasabapathy, MD</td>
<td>James Luketich, MD</td>
</tr>
<tr>
<td>Baylor College of Medicine</td>
<td>UPMC</td>
</tr>
<tr>
<td>Houston, Texas</td>
<td>Pittsburg, Pennsylvania</td>
</tr>
<tr>
<td>Lubin Arevalo, MD</td>
<td>Mohammed Othman, MD</td>
</tr>
<tr>
<td>Baylor College of Medicine</td>
<td>Baylor College of Medicine</td>
</tr>
<tr>
<td>Houston, Texas</td>
<td>Houston, Texas</td>
</tr>
<tr>
<td>Francis (Tripp) Buckley, MD</td>
<td>Kalpesh Patel, MD</td>
</tr>
<tr>
<td>Baylor Scott &amp; White</td>
<td>Baylor College of Medicine</td>
</tr>
<tr>
<td>Round Rock, Texas</td>
<td>Houston, Texas</td>
</tr>
<tr>
<td>Bryan Burt, MD, FACS</td>
<td>Brandon Smaglo, MD</td>
</tr>
<tr>
<td>Baylor College of Medicine</td>
<td>Baylor College of Medicine</td>
</tr>
<tr>
<td>Houston, Texas</td>
<td>Houston, Texas</td>
</tr>
<tr>
<td>Steve DeMeester, MD</td>
<td>Stuart Spechler, MD</td>
</tr>
<tr>
<td>The Oregon Clinic</td>
<td>Baylor Scott &amp; White</td>
</tr>
<tr>
<td>Portland, Oregon</td>
<td>Dallas, Texas</td>
</tr>
<tr>
<td>Hashem El-Serag, MD, MPH</td>
<td>David J. Sugarbaker, MD</td>
</tr>
<tr>
<td>Baylor College of Medicine</td>
<td>Baylor College of Medicine</td>
</tr>
<tr>
<td>Houston, Texas</td>
<td>Houston, Texas</td>
</tr>
<tr>
<td>Shawn Groth, MD</td>
<td>Stephen Swisher, MD</td>
</tr>
<tr>
<td>Baylor College of Medicine</td>
<td>UT MD Anderson Cancer Center</td>
</tr>
<tr>
<td>Houston, Texas</td>
<td>Houston, Texas</td>
</tr>
<tr>
<td>Matthew Hartwig, MD</td>
<td>Jon Wee, MD</td>
</tr>
<tr>
<td>Duke University Medical Center</td>
<td>Brigham and Women's Hospital</td>
</tr>
<tr>
<td>Durham, North Carolina</td>
<td>Boston, Massachusetts</td>
</tr>
<tr>
<td>Nisreen Husain, MD</td>
<td></td>
</tr>
<tr>
<td>Baylor College of Medicine</td>
<td></td>
</tr>
<tr>
<td>Houston, Texas</td>
<td></td>
</tr>
</tbody>
</table>

# Disclosure Statement

It is the intent of the Texas Heart Institute to ensure that its educational mission and its continuing medical education activities in particular, not be influenced by the special interests of individuals associated with its program. Having an affiliation with, or an interest in, any corporate organization does not prevent a speaker from making a presentation at an educational event, but the speaker's relationship must be revealed to the audience. When discussing therapeutic options, the presenter should use generic names. If it is necessary to use a trade name, then those of several companies should be used. Further, should the presentation include discussion of any unlabeled and investigational use of a commercial product, the presenter is required to disclose this to the audience.

In accordance with the guidelines of the Accreditation Council for Continuing Medical Education, everyone in a position to control content (faculty, planners, reviewers, and others who control content including their spouse/partner) has disclosed to Texas Heart Institute their relevant financial relationships with commercial interests. The Institute defines “relevant financial relationships” as financial relationships of the individual (including those of the individual's spouse or partner) in any amount occurring within the past 12 months that create a potential conflict of interest. The ACCME defines “commercial interest” as any entity producing, marketing, re-selling or distributing health care goods or services consumed by, or used on, patients.

The individuals below have disclosed the following relationships with commercial interests. 

Abbas Abbas, M.D. has received honoraria and is on the Speaker's Bureau for Intuitive Surgical and Boston Scientific.

Wasif Abidi, M.D., Ph.D. has nothing to disclose relevant to the content of his presentation.

Sharmila Anandasabapathy, M.D has nothing to disclose relevant to the content of her presentation.

Lubin Arevalo, M.D. has nothing to disclose relevant to the content of his presentation.

Francis (Tripp) Buckley, M.D. has received consulting fees and research grants from Torax.

Bryan Burt, M.D., FACS has nothing to disclose relevant to the content of his presentation.

Steve DeMeester, M.D. has served as researcher, speaker and consultant to Bard, Novadaq and CDX Diagnostics.

Hashem El-Serag, M.D., MPH has nothing to disclose relevant to the content of his presentation.

Shawn Groth, M.D. has served as a speaker for Intuitive.

Matthew Hartwig, M.D has served as a consultant for Medtronic and received research funding from Torax Medical.

Nisreen Husain, M.D. has nothing to disclose relevant to the content of her presentation.

Steven Leeds, M.D. has nothing to disclose relevant to the content of his presentation.

Antoon (Toni) Lerut, M.D., Ph.D. has nothing to disclose relevant to the content of his presentation.

James Luketich, M.D., FACS has stock in Johnson & Johnson, Express Scripts, Inc. Intuitive Surgical and Proctor & Gamble. He also receives royalties from Elsevier and serves as Deputy Editor for the *Annals of Thoracic Surgery*.

Mohammed Othman, M.D. serves as a consultant with Olympus, BSC and Abbvie.

Kalpesh Patel, M.D. has nothing to disclose relevant to the content of his presentation.

Brandon Smaglo, M.D. is on the speaker’s bureau for the drug Lonsurf at TAIHO Oncology, Inc.

Stuart Spechler, M.D. receives consulting fees from Takeda and Ironwood Pharmaceuticals and royalties from UpToDate.

David J. Sugarbaker, M.D. has nothing to disclose relevant to the content of his presentation.

Stephen Swisher, M.D. has nothing to disclose relevant to the content of his presentation.

Jon Wee, M.D. has served as a consultant for Medtronic.

The Planning Committee members have nothing to disclose.

The THI CME Staff have nothing to disclose.
Educational Grants

This activity has been planned to be well-balanced, objective, and scientifically rigorous. Information and opinions offered by speakers represent their viewpoints. Conclusions drawn by the audience should be derived from careful consideration of all available scientific information. Texas Heart Institute, Office of Continuing Medical Education, along with Baylor College of Medicine, gratefully acknowledges the following companies for providing educational grant support for this activity.

Pentax Medical

Exhibitors

Support for this conference has been provided in part by the following exhibitor, symposia and workshop sponsors:

EndoGastric Solutions
Erbe, USA
Ethicon
Gore
Merit Medical Endotek
Thoracent Inc.